Brentuximab Vedotin Nears European Approval for CTCL

November 14, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of brentuximab vedotin in adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy, Takeda Pharmaceuticals, which codevelops the antibody-drug conjugate with Seattle Genetics. The European Commission will now review the application for its final decision. If approved, brentuximab … (leggi tutto)